Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Microbot Medical Inc.NASDAQ: MBOT

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $12K fell 20.0% year over year, ahead of the -43.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 20.0% from the prior quarter. Over 3 fiscal years it compounded at -22.8% a year.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -20.0% holds above the trailing-twelve-month pace of -43.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12K+20.0% QoQ
Last fiscal yearDec 2025
$47K-48.4% YoY
LTMMar 2026
$44K-43.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.0%——
1 year-48.4%——
3-year CAGR-22.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
47K USD
Year-over-year change
-48.4%
4-year CAGR
-11.3%

Depreciation & Amortization vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -43.6% is the 8th highest of 10, against a peer median of -5.9%.
  • Depreciation & amortization amounts to 41.9% of revenue for MBOT, versus a peer median of 4.8%.
MBOT Competitors
Depreciation & Amortization for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$14.55M USD-5.9%+14.0%4.8%
RCELAVITA Medical, Inc.LTM Mar 2026$2.45M USD+69.9%+60.5%3.4%
CLNNClene Inc.LTM Mar 2026$1.45M USD-11.2%+13.6%1079.1%
ZTEKZentek Ltd.LTM Mar 2026CA$566.92K CAD-5.6%-0.7%341.3%
VANIVivani Medical, Inc.LTM Mar 2026$452K USD+12.2%+3.6%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$167K USD-73.0%-39.9%2.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$121K USD-27.5%-67.8%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$103.77K CAD-66.0%-14.3%—
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
MBOTMicrobot Medical Inc.LTM Mar 2026$44K USD-43.6%-22.8%41.9%
Peer median (excluding MBOT) —-5.9%+3.6%4.8%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00106K91K0
Gross Profit00(106K)(91K)0
Gross Margin—————
Research & Development6.15M7.74M5.72M6.63M6.28M
Selling, General & Admin5.41M5.58M4.13M5M8.25M
Operating Expenses11.36M13.28M9.75M11.53M14.74M
Depreciation & Amortization76K102K106K91K47K
EBITDA(11.24M)(13.34M)(10.63M)(11.35M)(13.1M)
EBITDA Margin—————
Operating Income(11.36M)(13.28M)(9.86M)(11.63M)(14.74M)
Operating Margin—————
Interest Income44K54K228K182K1.29M
Interest Expense00000
Other Income / Expenses44K113K(885K)182K1.6M
Income Before Tax(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Net Margin—————
EPS (Basic)(1.59)(1.81)(1.05)(0.73)(0.29)
EPS (Diluted)(1.59)(1.81)(1.05)(0.73)(0.29)
Weighted Avg Shares7.11M7.26M10.2M15.65M45.79M
Weighted Avg Shares (Diluted)7.11M7.26M10.2M15.65M45.79M

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.